β-Blockers in sepsis: Reexamining the evidence

Shock

Volumn 31, Issue 2, 2009, Pages 113-119

  Novotny, Nathan M ^a   Lahm, Tim ^b   Markel, Troy A ^a   Crisostomo, Paul R ^a   Wang, Meijing ^a   Wang, Yue ^a   Ray, Rinki ^a   Tan, Jiangning ^a   Al Azzawi, Dalia ^a   Meldrum, Daniel R ^a,b,c  

^a Dep of Orthopaedic Surgery   (United States)

^b Department of Pulmonary and Critical Care Medicine ^*  (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

adrenergic receptor; Cytokines; Endotoxin; Esmolol; LPS; Propranolol; Shock

Indexed keywords

ADRENALIN; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; ESMOLOL; GLUCOSE; ICI 118115; ICI 118511; PROPRANOLOL; UNCLASSIFIED DRUG;

CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; EVIDENCE BASED MEDICINE; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; HEART DISEASE; HEART FUNCTION; HUMAN; IMMUNOMODULATION; MORBIDITY; MORTALITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SEPSIS;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CYTOKINES; ENDOTOXINS; GLUCOSE; HEMODYNAMICS; HUMANS; HYPERTENSION; INFLAMMATION; LIPOPOLYSACCHARIDES; MODELS, BIOLOGICAL; MYOCARDIUM; PROPANOLAMINES; SEPSIS;

EID: 59649088065     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318180ffb6     Document Type: Review

References (103)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310, 2001.
2. Angus DC, Wax RS: Epidemiology of sepsis: an update. Crit Care Med 29:S109-S116, 2001.
3. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554, 2003.
4. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377, 2001.
5. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359-1367, 2001.
6. Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P: Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 31:359-366, 2003.
7. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296-327, 2008.
8. Poeze M, Ramsay G, Gerlach H, Rubulotta F, Levy M: An international sepsis survey: a study of doctors' knowledge and perception about sepsis. Crit Care 8:R409-R413, 2004.
9. Bone RC, Sibbald WJ, Sprung CL: The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101:1481-1483, 1992.
10. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250-1256, 2003.
11. Kher A, Wang M, Tsai BM, Pitcher JM, Greenbaum ES, Nagy RD, Patel KM, Wairiuko GM, Markel TA, Meldrum DR: Sex differences in the myocardial inflammatory response to acute injury. Shock 23:1-10, 2005.
12. Wang M, Meng X, Tsai B, Wang J-F, Turrentine M, Brown JW, Meldrum DR: Preconditioning up-regulates the soluble TNF receptor I response to endotoxin. J Surg Res 121:20-24, 2004.
13. Venet F, Chung C-S, Monneret G, Huang X, Horner B, Garber M, Ayala A: Regulatory T cell populations in sepsis and trauma. J Leukoc Biol 83:523-535, 2007.
14. Wisnoski N, Chung CS, Chen Y, Huang X, Ayala A: The contribution of CD4+ CD25+ T-regulatory-cells to immune suppression in sepsis. Shock 27:251-257, 2007.
15. Meng X, Ao L, Brown JM, Fullerton DA, Banerjee A, Harken AH: Nitric oxide synthase is not involved in cardiac contractile dysfunction in a rat model of endotoxemia without shock. Shock 7:111-118, 1997.
16. Wenzel RP: Treating sepsis. N Engl J Med 347:966-967, 2002.
17. Perl M, Chung CS, Garber M, Huang X, Ayala A: Contribution of anti-inflammatory/immune suppressive processes to the pathology of sepsis. Front Biosci 11:272-299, 2006.
18. Wesche-Soldato DE, Lomas-Neira JL, Perl M, Jones L, Chung CS, Ayala A: The role and regulation of apoptosis in sepsis. J Endotoxin Res 11:375-382, 2005.
19. Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A: The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 8:493-500, 2007.
20. Berk JL, Hagen JF, Beyer WH, Gerber MJ, Dochat GR: The treatment of endotoxin shock by beta adrenergic blockade. Ann Surg 169:74-81, 1969.
21. Prichard BN: Propranolol in the treatment of angina: a review. Postgrad Med J 52:35-41, 1976.
22. Shin J, Johnson JA: Pharmacogenetics of beta-blockers. Pharmacotherapy 27:874-887, 2007.
23. Kobilka BK: G protein coupled receptor structure and activation. Biochim Biophys Acta 1768:794-807, 2007.
24. Purves D: Neuroscience. Sunderland, MA: Sinauer Associates, 2004.
25. Berk JL, Hagen JF, Dunn J: The role of beta adrenergic blockade in the treatment of septic shock. Surg Gynecol Obstet 130:1025-1034, 1970.
26. Berk JL, Hagen JF, Maly G, Koo R: The treatment of shock with beta adrenergic blockade. Arch Surg 104:46-51, 1972.
27. Berk JL: The treatment of shock with beta adrenergic blockade. In: Bertelli A, Back N, eds.: Shock: Biochemical, Pharmacological, and Clinical Aspects. New York, NY: Plenum Press, Inc., 303-306, 1970.
28. Hinshaw L, Greenfield L, Archer L, Guenter C: Effects of endotoxin on myocardial hemodynamics, performance, and metabolism during beta adrenergic blockade. Proc Soc Exp Biol Med 137:1217-1224, 1971.
29. Chiolero R, Revelly JP, Tappy L: Energy metabolism in sepsis and injury. Nutrition 13:45S-51S, 1997.
30. Bergmann M, Gornikiewicz A, Sautner T, Waldmann E, Weber T, Mittlbock M, Roth E, Fugger R: Attenuation of catecholamine-induced immunosuppression in whole blood from patients with sepsis. Shock 12:421-427, 1999.
31. Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR: Reversal of ca-tabolism by beta-blockade after severe burns. N Engl J Med 345:1223-1229, 2001.
32. Chaudry IH, Hirasawa H, Baue AE: Impairment of reticuloendothelial system function with sepsis and its improvement with ATP-MgC12 plus glucose administration. Adv Shock Res 2:153-162, 1979.
33. Chaudry IH, Wichterman KA, Baue AE: Effect of sepsis on tissue adenine nucleotide levels. Surgery 85:205-211, 1979.
34. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH: Cecal ligation and puncture. Shock 24(suppl l):52-57, 2005.
35. Dickerson RN, Fried RC, Bailey PM, Stein TP, Mullen JL, Buzby GP: Effect of propranolol on nitrogen and energy metabolism in sepsis. J Surg Res 48:38-41, 1990.
36. Cavaillon JM, Annane D: Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res 12:151-170, 2006.
37. Trager K, DeBacker D, Radermacher P: Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 9:271-278, 2003.
38. Lager I, Attvall S, Eriksson BM, von Schenk H, Smith U: Studies on the insulin-antagonistic effect of catecholamines in normal man. Evidence for the importance of beta 2-receptors. Diabetologia 29:409-416, 1986.
39. Deibert DC, DeFronzo RA: Epinephrine-induced insulin resistance in man. J Clin Invest 65:717-721, 1980.
40. Lang CH: Sepsis-induced insulin resistance in rats is mediated by a beta-adrenergic mechanism. Am J Physiol 263:E703-E711, 1992.
41. Shaw JH, Holdaway CM, Humberstone DA: Metabolic intervention in surgical patients: the effect of alpha-or beta-blockade on glucose and protein metabolism in surgical patients receiving total parenteral nutrition. Surgery 103:520-525, 1988.
42. Gore DC, Wolfe RR: Hemodynamic and metabolic effects of selective betal adrenergic blockade during sepsis. Surgery 139:686-694, 2006.
43. Hargrove DM, Bagby GJ, Lang CH, Spitzer JJ: Adrenergic blockade prevents endotoxin-induced increases in glucose metabolism. Am J Physiol 255: E629-E635, 1988.
44. Herndon DN, Dasu MR, Wolfe RR, Barrow RE: Gene expression profiles and protein balance in skeletal muscle of burned children after beta-adrenergic blockade. Am J Physiol Endocrinol Metab 285:E783-E789, 2003.
45. Fong YM, Marano MA, Moldawer LL, Wei H, Calvano SE, Kenney JS, Allison AC, Cerami A, Shires GT, Lowry SF: The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85:1896-1904, 1990.
46. Bessey PQ, Watters JM, Aoki TT, Wilmore DW: Combined hormonal infusion simulates the metabolic response to injury. Ann Surg 200:264-281, 1984.
47. O'Dwyer MJ, Mankan AK, Stordeur P, O'Connell B, Duggan E, White M, Kelleher DP, McManus R, Ryan T: The occurrence of severe sepsis and septic shock are related to distinct patterns of cytokine gene expression. Shock 26:544-550, 2006.
48. Chuang CC, Wang ST, Chen WC, Chen CC, Hor LI, Chuang AY: Increases in serum macrophage migration inhibitory factor in patients with severe sepsis predict early mortality. Shock 27:503-506, 2007.
49. Dinarello CA, Cannon JG: Cytokine measurements in septic shock. Ann Intern Med 119:853-854, 1993.
50. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol Regul Integr Comp Physiol 274:R577-R595, 1998.
51. Jean-Baptiste E: Cellular mechanisms in sepsis. J Intensive Care Med 22: 63-72, 2007.
52. Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D: Cytokine cascade in sepsis. Scand J Infect Dis 35:535-544, 2003.
53. Markel TA, Crisostomo PR, Wairiuko GM, Pitcher J, Tsai BM, Meldrum DR: Cytokines in necrotizing enterocolitis. Shock 25:329-337, 2006.
54. Finnerty CC, Herndon DN, Chinkes DL, Jeschke MG: Serum cytokine differences in severely burned children with and without sepsis. Shock 27:4-9, 2007.
55. Vary TC, Deiter G, Lang CH: Cytokine-triggered decreases in levels of phosphorylated eukaryotic initiation factor 4G in skeletal muscle during sepsis. Shock 26:631-636, 2006.
56. Brunialti MK, Martins PS, Barbosa de Carvalho H, Machado FR, Barbosa LM, Salomao R: TLR2, TLR4, CD14, CD11B, and CD11C expressions on monocytes surface and cytokine production in patients with sepsis, severe sepsis, and septic shock. Shock 25:351-357, 2006.
57. Bedirli A, Kerem M, Pasaoglu H, Akyurek N, Tezcaner T, Elbeg S, Memis L, Sakrak O: Beta-glucan attenuates inflammatory cytokine release and prevents acute lung injury in an experimental model of sepsis. Shock 27:397-401, 2007.
58. Clark JA, Clark AT, Hotchkiss RS, Buchman TG, Coopersmith CM: Epidermal growth factor treatment decreases mortality and is associated with improved gut integrity in sepsis. Shock 30:36-42, 2008.
59. Dinarello CA, Abraham E: Does blocking cytokines in sepsis work? Am J Respir Crit Care Med 166:1156-1157, 2002.
60. Cain BS, Meldrum DR, Harken AH, Mclntyre RC Jr: The physiologic basis for anticytokine clinical trials in the treatment of sepsis. J Am Coll Surg 186:337-350, 1998.
61. Bruhn A, Verdant C, Vercruysse V, Su F, Vray B, Vincent JL: Effects of dexamethasone on macrophage migration inhibitory factor production in sepsis. Shock 26:169-173, 2006.
62. Shapiro NI, Yano K, Okada H, Fischer C, Howell M, Spokes KC, Ngo L, Angus DC, Aird WC: A prospective, observational study of soluble Flt-1 and vascular endothelial growth factor in sepsis. Shock 29:452-457, 2008.
63. Angele MK, Frantz MC, Chaudry IH: Gender and sex hormones influence the response to trauma and sepsis: potential therapeutic approaches. Clinics 61:479-488, 2006.
64. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150, 2003.
65. Russell JA: Management of sepsis. N Engl J Med 355:1699-1713, 2006.
66. Appay V, Rowland-Jones SL: RANTES: a versatile and controversial chemokine. Trends Immunol 22:83-87, 2001.
67. Hallsworth MP, Twort CHC, Lee TH, Hirst SJ: [beta]2-Adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells. Br J Pharmacol 132:729-741, 2001.
68. Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL: Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 328:1457-1460, 1993.
69. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, Harken AH: Tumor necrosis factor-alpha and interleukin-lbeta synergistically depress human myocardial function. Crit Care Med 27:1309-1318, 1999.
70. Deitch EA: Tumor necrosis factor as the proximal mediator of sepsis - or this too will pass. Crit Care Med 23:1457-1458, 1995.
71. Boost KA, Flondor M, Hofstetter C, Platacis I, Stegewerth K, Hoegl S, Nguyen T, Muhl H, Zwissler B: The beta-adrenoceptor antagonist propranolol counteracts anti-inflammatory effects of isoflurane in rat endotoxemia. Acta Anaesthesiol Scand 51:900-908, 2007.
72. Deng J, Muthu K, Gamelli R, Shankar R, Jones SB: Adrenergic modulation of splenic macrophage cytokine release in polymicrobial sepsis. Am J Physiol Cell Physiol 287:C730-C736, 2004.
73. Muthu K, Deng J, Gamelli R, Shankar R, Jones SB: Adrenergic modulation of cytokine release in bone marrow progenitor-derived macrophage following polymicrobial sepsis. J Neuroimmunol 158:50-57, 2005.
74. Suzuki T, Morisaki H, Serita R, Yamamoto M, Kotake Y, Ishizaka A, Takeda J: Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 33:2294-2301, 2005.
75. Meldrum DR: Beta-blockade during sepsis: inspired or insane? Crit Care Med 33:2433-2434, 2005.
76. Schwacha MG, Schneider CP, Chaudry IH: Differential expression and tissue compartmentalization of the inflammatory response following thermal injury. Cytokine 17:266-274, 2002.
77. Dinarello CA: Interleukin-lbeta. Crit Care Med 33:S460-S462, 2005.
78. Sharma R, Tepas JJ 3rd, Hudak ML, Mollitt DL, Wludyka PS, Teng RJ, Premachandra BR: Neonatal gut barrier and multiple organ failure: role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis. J Pediatr Surg 42:454-461, 2007.
79. Jeschke MG, Norbury WB, Finnerty CC, Branski LK, Herndon DN: Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. J Trauma 62:676-681, 2007.
80. Schmitz D, Wilsenack K, Lendemanns S, Schedlowski M, Oberbeck R: Beta-adrenergic blockade during systemic inflammation: impact on cellular immune functions and survival in a murine model of sepsis. Resuscitation 72:286-294, 2007.
81. Oberbeck R, Schmitz D, Wilsenack K, Schuler M, Pehle B, Schedlowski M, Exton MS: Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis. Neuroimmunomodulation 11:214-223, 2004.
82. Schneider CP, Schwacha MG, Chaudry IH: The role of interleukin-10 in the regulation of the systemic inflammatory response following trauma-hemorrhage. Biochim Biophys Acta 1689:22-32, 2004.
83. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765, 2001.
84. Scumpia PO, Moldawer LL: Biology of interleukin-10 and its regulatory roles in sepsis syndromes. Crit Care Med 33:S468-S471, 2005.
85. Rajan S, Vyas D, Clark AT, Woolsey CA, Clark JA, Hotchkiss RS, Buchman TG, Coopersmith CM: Intestine-specific overexpression of IL-10 improves survival in polymicrobial sepsis. Shock 29:483-489, 2008.
86. Sharma AC: Sepsis-induced myocardial dysfunction. Shock 28:265-269, 2007.
87. Merx MW, Weber C: Sepsis and the heart. Circulation 116:793-802, 2007.
88. Horton JW: A model of myocardial inflammation and dysfunction in burn complicated by sepsis. Shock 28:326-333, 2007.
89. Mink SN, Kasian K, Jacobs H, Cheng ZQ, Light RB: N,Nô- Diacetylchitobiose, an inhibitor of lysozyme, reverses myocardial depression and lessens norepinephrine requirements in escherichia coli sepsis in dogs. Shock 29:681-687, 2008.
90. Abraham E, Singer M: Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 35:2408-2416, 2007.
91. Yang S, Chung CS, Ayala A, Chaudry IH, Wang P: Differential alterations in cardiovascular responses during the progression of polymicrobial sepsis in the mouse. Shock 17:55-60, 2002.
92. Jarrar D, Chaudry IH, Wang P: Organ dysfunction following hemorrhage and sepsis: mechanisms and therapeutic approaches (review), lnt J Mol Med 4:575-583, 1999.
93. Pomerantz BJ, Harken AH: Ischemia and the myocardium. Adv Card Surg 12:23-36, 2000.
94. Haider HK, Elmadbouh I, Jean-Baptiste M, Ashraf M: Nonviral vector gene modification of stem cells for myocardial repair. Mol Med 14:79-86, 2008.
95. Wang Y, Ahmad N, Wang B, Ashraf M: Chronic preconditioning: a novel approach for cardiac protection. Am J Physiol Heart Circ Physiol 292: H2300-H2305, 2007.
96. Haider H, Ashraf M: Bone marrow stem cell transplantation for cardiac repair. Am J Physiol Heart Circ Physiol 288:H2557-H2567, 2005.
97. Haider H, Ashraf M: Bone marrow stem cells in the infarcted heart. Coron Artery Dis 16:99-103, 2005.
98. Hagiwara S, Iwasaka H, Shingu C, Noguchi T: Effect of enteral vs. parenteral nutrition on inflammation and cardiac function in a rat model of endotoxin-induced sepsis. Shock 30:280-284, 2008.
99. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA. Parrillo JE: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100:483-490, 1984.
100. Hjalmarson A: Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 80: 35J-39J, 1997.
101. Mangano DT, Layug EL, Wallace A, Tateo I: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 335:1713-1720, 1996.
102. Walvatne CS, Johnson AS, Wojcik LJ, Cerra FB: Cardiovascular response to acute and chronic endotoxemia in an awake, volume-resuscitated, canine model. Shock 3:299-306, 1995.
103. Markley K, Smallman ET, Briggs LW: Early mortality and temperature regulation in burned mice following administration of catecholamines and adrenergic receptor blocking drugs. J Trauma 19:512-518, 1979.